Accumulation and distribution of doxorubicin in tumour spheroids: The influence of acidity and expression of P-glycoprotein

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1179-1190

  Mellor, Howard R ^a   Callaghan, Richard ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bioenergetic metabolism; Cancer chemotherapy; Doxorubicin; Drug resistance; Hypoxia; P glycoprotein; Solid tumours; Tumour acidity; Tumour spheroid

Indexed keywords

DACTINOMYCIN; DOXORUBICIN; GLYCOPROTEIN P; PACLITAXEL; TARIQUIDAR;

ARTICLE; CELL STRAIN HT29; CELL VIABILITY; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; HYPOXIA; IC 50; METABOLIC ACIDOSIS; OVARY ADENOCARCINOMA; PH MEASUREMENT; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; TUMOR MODEL; TUMOR SPHEROID; TUMOR VOLUME;

ACIDS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOHISTOCHEMISTRY; MICROSCOPY, FLUORESCENCE; NEOPLASMS; P-GLYCOPROTEIN; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 82455212096     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1598-8     Document Type: Article

References (69)

1. Baguley BC (2010) Multidrug resistance in cancer. Methods Mol Biol 596:1-14. doi: 10.1007/978-1-60761-416-6-1
2. Gillet J-P, Gottesman MM (2010) Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596:47-76. doi: 10.1007/978-1-60761-416-6-4
3. HR Mellor R Callaghan 2008 Resistance to chemotherapy in cancer: a complex and integrated cellular response Pharmacology 81 4 275 300 18259091 10.1159/000115967 1:CAS:528:DC%2BD1cXlsFOgs70%3D (Pubitemid 351666917)
4. O Tredan CM Galmarini K Patel IF Tannock 2007 Drug resistance and the solid tumor microenvironment J Natl Cancer Inst 99 19 1441 1454 djm135[pii]10.1093/jnci/djm135 17895480 10.1093/jnci/djm135 1:CAS:528: DC%2BD2sXht1yltbrO
5. P Hietanen C Blomqvist VM Wasenius E Niskanen K Franssila S Nordling 1995 Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 71 5 1029 1032 7734295 10.1038/bjc.1995.198 1:STN:280:DyaK2M3lt1SntQ%3D%3D
6. RC Jackson 1989 The problem of the quiescent cancer cell Adv Enzyme Regul 29 27 46 2633613 10.1016/0065-2571(89)90092-7 1:CAS:528:DyaK3cXptFegtg%3D%3D
7. WY Siu T Arooz RY Poon 1999 Differential responses of proliferating versus quiescent cells to adriamycin Exp Cell Res 250 1 131 141 10.1006/excr.1999.4551S0014-4827(99)94551-2[pii] 10388527 10.1006/excr.1999.4551 1:CAS:528:DyaK1MXktV2kt78%3D (Pubitemid 29391577)
8. J Jiricny 2006 The multifaceted mismatch-repair system Nat Rev Mol Cell Biol 7 5 335 346 16612326 10.1038/nrm1907 1:CAS:528:DC%2BD28XjslSktrs%3D
9. R Rosell M Taron A Barnadas G Scagliotti C Sarries B Roig 2003 Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer Cancer Control 10 4 297 305 12915808 (Pubitemid 36919542)
10. RN Trivedi KH Almeida JL Fornsaglio S Schamus RW Sobol 2005 The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death Cancer Res 65 14 6394 6400 16024643 10.1158/0008-5472.CAN-05-0715 1:CAS:528:DC%2BD2MXmt1egt7c%3D (Pubitemid 40994427)
11. X Deng SM Kornblau PP Ruvolo WS May Jr 2001 Regulation of Bcl2 phosphorylation and potential significance for leukemic cell chemoresistance J Natl Cancer Inst Monogr 2000 28 30 37
12. LE Post 2002 Selectively replicating adenoviruses for cancer therapy: an update on clinical development Curr Opin Investig Drugs 3 12 1768 1772 12528315 1:CAS:528:DC%2BD3sXhtlKktbw%3D (Pubitemid 36266725)
13. J Sjostrom C Blomqvist K von Boguslawski NO Bengtsson I Mjaaland P Malmstrom B Ostenstadt E Wist V Valvere S Takayama JC Reed E Saksela 2002 The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer Clin Cancer Res 8 3 811 816 11895913 1:CAS:528:DC%2BD38XislOqtb0%3D (Pubitemid 34742112)
14. G Giaccone AF Gazdar H Beck F Zunino G Capranico 1992 Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression Cancer Res 52 7 1666 1674 1312895 1:CAS:528:DyaK38XitVOntLg%3D
15. Y Gokmen-Polar D Escuin CD Walls SE Soule Y Wang KL Sanders TM Lavallee M Wang BD Guenther P Giannakakou GW Sledge Jr 2005 Beta-tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells Cancer Res 65 20 9406 9414 16230404 10.1158/0008-5472.CAN-05-0088 (Pubitemid 41508009)
16. M Hari F Loganzo T Annable X Tan S Musto DB Morilla JH Nettles JP Snyder LM Greenberger 2006 Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules Mol Cancer Ther 5 2 270 278 16505100 10.1158/1535-7163.MCT-05-0190 1:CAS:528:DC%2BD28XhvVels7o%3D
17. Y Matsumoto H Takano S Nagao T Fojo 2001 Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure Jpn J Cancer Res 92 9 968 974 11572765 1:CAS:528:DC%2BD3MXotlajtb8%3D (Pubitemid 32970438)
18. B Desoize J Jardillier 2000 Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 36 2-3 193 207 S104084280000086X[pii] 11033306 10.1016/S1040-8428(00)00086-X 1:STN:280:DC%2BD3M%2FotFSjuw%3D%3D
19. IF Tannock CM Lee JK Tunggal DS Cowan MJ Egorin 2002 Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy Clin Cancer Res 8 3 878 884 11895922 1:CAS:528:DC%2BD38XislOqurw%3D (Pubitemid 34742121)
20. MA Konerding E Fait A Gaumann 2001 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon Br J Cancer 84 10 1354 1362 10.1054/bjoc.2001.1809S0007092001918099[pii] 11355947 10.1054/bjoc.2001.1809 1:STN:280:DC%2BD3M3msVWmuw%3D%3D (Pubitemid 32522104)
21. S Modok P Hyde HR Mellor T Roose R Callaghan 2006 Diffusivity and distribution of vinblastine in three-dimensional tumour tissue: Experimental and mathematical modelling Eur J Cancer 42 2404 2413 16901688 10.1016/j.ejca.2006. 05.020 1:CAS:528:DC%2BD28XptlyktL4%3D (Pubitemid 44316902)
22. RT Tong Y Boucher SV Kozin F Winkler DJ Hicklin RK Jain 2004 Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 11 3731 3736 10.1158/0008-5472.CAN-04-007464/11/3731[pii] 15172975 10.1158/0008-5472.CAN-04-0074 1:CAS:528:DC%2BD2cXksVKgur8%3D (Pubitemid 38697278)
23. CH Heldin K Rubin K Pietras A Ostman 2004 High interstitial fluid pressure - an obstacle in cancer therapy Nat Rev Cancer 4 10 806 813 nrc1456[pii]10.1038/nrc1456 15510161 10.1038/nrc1456 1:CAS:528: DC%2BD2cXos1ymu7s%3D (Pubitemid 39331152)
24. KJ Patel IF Tannock 2009 The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors BMC Cancer 9 356 1471-2407-9-356[pii]10.1186/1471-2407-9-356 19807929 10.1186/1471-2407-9-356
25. AJ Primeau A Rendon D Hedley L Lilge IF Tannock 2005 The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors Clin Cancer Res 11 24 8782 8788 11/24/8782[pii]10.1158/1078-0432.CCR-05-1664 16361566 10.1158/1078-0432.CCR-05-1664 1:CAS:528:DC%2BD2MXhtlWrsbjK (Pubitemid 43005929)
26. LH Matherly 2001 Molecular and cellular biology of the human reduced folate carrier Prog Nucleic Acid Res Mol Biol 67 131 162 11525381 10.1016/S0079-6603(01)67027-2 1:CAS:528:DC%2BD3MXntFCgtro%3D (Pubitemid 33804643)
27. R Gorlick E Goker T Trippett P Steinherz Y Elisseyeff M Mazumdar WF Flintoff JR Bertino 1997 Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression Blood 89 3 1013 1018 9028333 1:CAS:528:DyaK2sXptV2luw%3D%3D (Pubitemid 27121295)
28. I Ifergan I Meller J Issakov YG Assaraf 2003 Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity Cancer 98 9 1958 1966 10.1002/cncr.11741 14584080 10.1002/cncr.11741 1:CAS:528:DC%2BD3sXpt1art7w%3D (Pubitemid 37310240)
29. MM Gottesman T Fojo SE Bates 2002 Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2 1 48 58 11902585 10.1038/nrc706 1:CAS:528:DC%2BD38XhvF2jtL8%3D (Pubitemid 37328807)
30. S Modok HR Mellor R Callaghan 2006 Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer Curr Opin Pharmacol 6 4 350 354 16690355 10.1016/j.coph.2006.01.009 1:CAS:528:DC%2BD28XmslCqu7Y%3D (Pubitemid 44026037)
31. D Keppler J Konig 2000 Hepatic secretion of conjugated drugs and endogenous substances Semin Liver Dis 20 3 265 272 11076395 10.1055/s-2000-9391 1:CAS:528:DC%2BD3cXotVOmurw%3D
32. DW Loe KC Almquist SP Cole RG Deeley 1996 ATP-dependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids J Biol Chem 271 16 9683 9689 8621644 10.1074/jbc.271.16.9683 1:CAS:528:DyaK28XisFSls7s%3D (Pubitemid 26137375)
33. DW Loe RK Stewart TE Massey RG Deeley SP Cole 1997 ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene Mol Pharmacol 51 6 1034 1041 9187270 1:CAS:528:DyaK2sXjvFWlu7k%3D (Pubitemid 27249137)
34. DJ Adams 2005 The impact of tumor physiology on camptothecin-based drug development Curr Med Chem Anticancer Agents 5 1 1 13 15720257 10.2174/1568011053352596 1:CAS:528:DC%2BD2MXhvFKmtQ%3D%3D (Pubitemid 40081290)
35. MG Vander Heiden LC Cantley CB Thompson 2009 Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 324 5930 1029 1033 324/5930/1029[pii]10.1126/science.1160809 19460998 10.1126/science.1160809 1:CAS:528:DC%2BD1MXmtVKlsbg%3D
36. S Yeluri B Madhok KR Prasad P Quirke DG Jayne 2009 Cancer's craving for sugar: an opportunity for clinical exploitation J Cancer Res Clin Oncol 135 7 867 877 10.1007/s00432-009-0590-8 19415328 10.1007/s00432-009-0590-8 1:STN:280:DC%2BD1MzntlGjsA%3D%3D
37. O Warburg 1956 On the origin of cancer cells Science 123 3191 309 314 13298683 10.1126/science.123.3191.309 1:STN:280:DyaG28%2FltV2ktQ%3D%3D
38. LA Shimoda M Fallon S Pisarcik J Wang GL Semenza 2006 HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes Am J Physiol Lung Cell Mol Physiol 291 5 L941 L949 00528.2005[pii]10.1152/ajplung.00528.2005 16766575 10.1152/ajplung.00528.2005 1:CAS:528:DC%2BD28Xht1GnsLrJ (Pubitemid 44772056)
39. MS Ullah AJ Davies AP Halestrap 2006 The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism J Biol Chem 281 14 9030 9037 M511397200[pii]10. 1074/jbc.M511397200 16452478 10.1074/jbc.M511397200 1:CAS:528: DC%2BD28XjtVSkt7Y%3D (Pubitemid 43864615)
40. CC Wykoff NJ Beasley PH Watson KJ Turner J Pastorek A Sibtain GD Wilson H Turley KL Talks PH Maxwell CW Pugh PJ Ratcliffe AL Harris 2000 Hypoxia-inducible expression of tumor-associated carbonic anhydrases Cancer Res 60 24 7075 7083 11156414 1:CAS:528:DC%2BD3MXjsVOhtw%3D%3D (Pubitemid 32059187)
41. KM Comerford TJ Wallace J Karhausen NA Louis MC Montalto SP Colgan 2002 Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene Cancer Res 62 12 3387 3394 12067980 1:CAS:528:DC%2BD38XkslWqsLc%3D (Pubitemid 34651384)
42. M Wartenberg FC Ling M Muschen F Klein H Acker M Gassmann K Petrat V Putz J Hescheler H Sauer 2003 Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species FASEB J 17 3 503 505 10.1096/fj.02- 0358fje02-0358fje[pii] 12514119 1:CAS:528:DC%2BD3sXitFaqurY%3D
43. CM Lee IF Tannock 2006 Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration Br J Cancer 94 6 863 869 6603010[pii]10.1038/sj.bjc.6603010 16495919 10.1038/sj.bjc.6603010 1:CAS:528:DC%2BD28Xis1GktLw%3D
44. HR Mellor DJ Ferguson R Callaghan 2005 A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs Br J Cancer 93 3 302 309 16052217 10.1038/sj.bjc.6602710 1:CAS:528: DC%2BD2MXmvFensb4%3D (Pubitemid 43080032)
45. HR Mellor S Snelling MD Hall S Modok M Jaffar TW Hambley R Callaghan 2005 The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum (IV) complexes Biochem Pharmacol 70 8 1137 1146 16139250 10.1016/j.bcp.2005.07.016 1:CAS:528:DC%2BD2MXhtVWnsLzP (Pubitemid 41317508)
46. C Martin J Walker A Rothnie R Callaghan 2003 The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models Br J Cancer 89 1581 1589 14562035 10.1038/sj.bjc.6601300 1:CAS:528:DC%2BD3sXotFeksbw%3D (Pubitemid 37386618)
47. J Walker C Martin R Callaghan 2004 Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy Eur J Cancer 40 594 605 14962729 10.1016/j.ejca.2003.09.036 1:CAS:528: DC%2BD2cXhtFWjtrw%3D (Pubitemid 38220779)
48. A De Milito S Fais 2005 Tumor acidity, chemoresistance and proton pump inhibitors Future Oncol 1 6 779 786 10.2217/14796694.1.6.779 16556057 10.2217/14796694.1.6.779
49. Ta Henning Mb Kraus Ma Brischwein Otto AMa Wolf Ba 2004 Relevance of tumor microenvironment for progression, therapy and drug development Anti-Cancer Drugs 15 1 7 14 15090737 10.1097/00001813-200401000-00002 1:CAS:528: DC%2BD2cXjtVaqu70%3D (Pubitemid 39140166)
50. JP Marie DC Zhou S Gurbuxani O Legrand R Zittoun 1996 MDR1/P-glycoprotein in haematological neoplasms Eur J Cancer 32A 6 1034 1038 8763345 10.1016/0959-8049(96)00055-X 1:STN:280:DyaK283ps1GmtQ%3D%3D
51. BJ Trock F Leonessa R Clarke 1997 Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance J Natl Cancer Inst 89 13 917 931 9214671 10.1093/jnci/89.13.917 1:STN:280:DyaK2szlslensA%3D%3D (Pubitemid 27282064)
52. L Liu X Ning L Sun H Zhang Y Shi C Guo S Han J Liu S Sun Z Han K Wu D Fan 2008 Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer Cancer Sci 99 1 121 128 CAS643[pii]10.1111/j. 1349-7006.2007.00643.x 17953712 10.1111/j.1349-7006.2008.00922.x 1:CAS:528:DC%2BD1cXnsFWlsA%3D%3D (Pubitemid 350239040)
53. C Fradette J Batonga S Teng M Piquette-Miller P du Souich 2007 Animal models of acute moderate hypoxia are associated with a down-regulation of CYP1A1, 1A2, 2B4, 2C5, and 2C16 and up-regulation of CYP3A6 and P-glycoprotein in liver Drug Metab Dispos 35 5 765 771 dmd.106.013508[pii]10.1124/dmd.106. 013508 17303624 10.1124/dmd.106.013508 1:CAS:528:DC%2BD2sXlsVWmtbg%3D (Pubitemid 46641547)
54. L Xiao-Dong Y Zhi-Hong Y Hui-Wen 2008 Repetitive/temporal hypoxia increased P-glycoprotein expression in cultured rat brain microvascular endothelial cells in vitro Neurosci Lett 432 3 184 187 S0304-3940(07)01279- 7[pii]10.1016/j.neulet.2007.12.017 18241990 10.1016/j.neulet.2007.12.017
55. C Lotz DK Kelleher B Gassner M Gekle P Vaupel O Thews 2007 Role of the tumor microenvironment in the activity and expression of the p-glycoprotein in human colon carcinoma cells Oncol Rep 17 1 239 244 17143504 1:CAS:528: DC%2BD2sXhtFagtbk%3D
56. C Sauvant M Nowak C Wirth B Schneider A Riemann M Gekle O Thews 2008 Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38 Int J Cancer 123 11 2532 2542 10.1002/ijc.23818 18729196 10.1002/ijc.23818 1:CAS:528:DC%2BD1cXhtlyru7vJ
57. O Thews B Gassner DK Kelleher M Gekle 2008 Activity of drug efflux transporters in tumor cells under hypoxic conditions Adv Exp Med Biol 614 157 164 10.1007/978-0-387-74911-2-19 18290326 10.1007/978-0-387-74911-2-19 1:CAS:528:DC%2BC3cXhtlemsLnP
58. PA Netti LM Hamberg JW Babich D Kierstead W Graham GJ Hunter GL Wolf A Fischman Y Boucher RK Jain 1999 Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules Proc Natl Acad Sci USA 96 6 3137 3142 10077650 10.1073/pnas.96.6.3137 1:CAS:528:DyaK1MXhvFykt7k%3D (Pubitemid 29148857)
59. M Stohrer Y Boucher M Stangassinger RK Jain 2000 Oncotic pressure in solid tumors is elevated Cancer Res 60 15 4251 4255 10945638 1:CAS:528:DC%2BD3cXlvFOktb4%3D (Pubitemid 30636613)
60. P Swietach S Patiar CT Supuran AL Harris RD Vaughan-Jones 2009 The role of carbonic anhydrase 9 in regulating extracellular and intracellular ph in three-dimensional tumor cell growths J Biol Chem 284 30 20299 20310 M109.006478[pii]10.1074/jbc.M109.006478 19458084 10.1074/jbc.M109.006478 1:CAS:528:DC%2BD1MXos1ensb4%3D
61. K Glunde H Dümann H-P Juretschke D Leibfritz 2002 Na < sup >+/H < sup >+ exchange subtype 1 inhibition during extracellular acidification and hypoxia in glioma cells J Neurochem 80 1 36 44 11796741 10.1046/j.0022-3042.2001.00661.x 1:CAS:528:DC%2BD38Xjt1WqtQ%3D%3D (Pubitemid 34614575)
62. DA Whittingtons JH Grubb A Waheed GN Shah WS Sly DW Christianson 2004 Expression, assay, and structure of the extracellular domain of murine carbonic anhydrase XIV J Biol Chem 279 8 7223 7228 10.1074/jbc.M310809200 10.1074/jbc.M310809200 1:CAS:528:DC%2BD2cXht1Cksbk%3D (Pubitemid 38248870)
63. J-Y Winum M Rami A Scozzafava J-L Montero C Supuran 2008 Carbonic anhydrase IX: a new druggable target for the design of antitumor agents Med Res Rev 28 3 445 463 17880011 10.1002/med.20112 1:CAS:528:DC%2BD1cXmsVyltLk%3D (Pubitemid 351590542)
64. S Kaluz M Kaluzová S-Y Liao M Lerman EJ Stanbridge 2009 Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta (BBA) - Rev Cancer 1795 2 162 172 10.1016/j.bbcan.2009.01.001 1:CAS:528:DC%2BD1MXjvVWjsro%3D
65. S Rodriguez-Enriquez JC Gallardo-Perez A Aviles-Salas A Marin-Hernandez L Carreno-Fuentes V Maldonado-Lagunas R Moreno-Sanchez 2008 Energy metabolism transition in multi-cellular human tumor spheroids J Cell Physiol 216 1 189 197 10.1002/jcp.21392 18264981 10.1002/jcp.21392 1:CAS:528:DC%2BD1cXnt1ektrk%3D (Pubitemid 351813110)
66. BE Enerson LR Drewes 2003 Molecular features, regulation, and function of monocarboxylate transporters: Implications for drug delivery J Pharm Sci 92 8 1531 1544 12884241 10.1002/jps.10389 1:CAS:528:DC%2BD3sXmtFeksbs%3D (Pubitemid 36929674)
67. P Sonveaux F Vegran T Schroeder MC Wergin J Verrax ZN Rabbani CJ De Saedeleer KM Kennedy C Diepart BF Jordan MJ Kelley B Gallez ML Wahl O Feron MW Dewhirst 2008 Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice J Clin Invest 118 12 3930 3942 36843[pii]10.1172/JCI36843 19033663 1:CAS:528:DC%2BD1cXhsVKgu7rI
68. GL Semenza 2008 Tumor metabolism: cancer cells give and take lactate J Clin Invest 118 12 3835 3837 19033652 1:CAS:528:DC%2BD1cXhsVKgu73P
69. E Miraglia D Viarisio C Riganti C Costamagna D Ghigo A Bosia 2005 Na +/H + exchanger activity is increased in doxorubicin-resistant human colon cancer cells and its modulation modifies the sensitivity of the cells to doxorubicin Int J Cancer 115 6 924 929 15729714 10.1002/ijc.20959 1:CAS:528: DC%2BD2MXltlWrsLs%3D (Pubitemid 40791833)